Author:
Pichichero Michael,Papa Thomas,Blatter Mark,Mitchell Douglas,Kratz Richard,Sneed Jane,Bassily Ehab,Casey Janet,Gilmet Gregory
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Infectious Diseases,Microbiology (medical),Pediatrics, Perinatology and Child Health
Reference19 articles.
1. Meningococcal disease.;Rosenstein;N Engl J Med,2001
2. Centers for Disease Control and Prevention. Meningococcal disease and college students: recommendations of the Advisory Committee on Immunization Practices (ACIP).;MMWR Morb Mortal Wkly Rep,2000
3. Centers for Disease Control and Prevention. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).;MMWR Morb Mortal Wkly Rep,2000
4. Safety, reactogenicity, and immunogenicity of a tetravalent meningococcal polysaccharide-diphtheria toxoid conjugate vaccine given to healthy adults.;Campbell;J Infect Dis,2002
5. Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children.;Pichichero;Pediatr Infect Dis J,2005
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Antibody avidity to pertussis toxin after acellular pertussis vaccination and infection;Emerging Microbes & Infections;2023-02-16
2. Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020;MMWR. Recommendations and Reports;2020-09-25
3. A Safety and Immunogenicity Study of a Single Dose of a Meningococcal (Groups A, C, W, and Y) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (MEN-ACWY-D) in Healthy Japanese Participants;Japanese Journal of Infectious Diseases;2018-11-30
4. Safety and immunogenicity of a single dose of a quadrivalent meningococcal conjugate vaccine (MenACYW–D): a multicenter, blind-observer, randomized, phase III clinical trial in the Republic of Korea;International Journal of Infectious Diseases;2016-04
5. Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants;Human Vaccines & Immunotherapeutics;2016-02